Allergies News and Research

Latest Allergies News and Research

NIAID renews contract to support inner city asthma research

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has renewed the contract to continue studying asthma in children living in lower-income, inner-city environments.

5 Nov 2009

Stress-reduction workshops for women with history of breast cancer

Are you stressed? Do you have a family history of breast cancer? Health SMART is a study is being conducted by researchers at Fred Hutchinson Cancer Research Center to see how stress-reduction workshops can help women with a family history of breast cancer manage their everyday stresses and cancer-risk concerns.

4 Nov 2009

Aerocrine, PSEC enters into a long-term development agreement

Aerocrine AB today announced that Aerocrine and Panasonic Shikoku Electronics, CO., LTD (PSEC) have entered into a long-term agreement to develop, manufacture and market new generation products for airway inflammation monitoring using exhaled nitric oxide.

4 Nov 2009

MedInformatix demonstrates its PM and EMR Solution at 2009 AAO Conference

MedInformatix, a leading provider of software solutions for the healthcare industry, announced the tenth anniversary of its relationships with several prominent Midwestern ophthalmology practices at the 2009 American Academy of Ophthalmology (AAO) Conference in San Francisco. In each case, the practices showcase the benefits of MedInformatix's Practice Management (PM) and Electronic Medical Records (EMR) Solution.

4 Nov 2009

Study sheds light on the rise in childhood asthma in developed countries

A University of Adelaide study may have shed light on the rise in childhood asthma in developed countries like Australia in recent decades.

4 Nov 2009

Teva Pharmaceutical launches Fexofenadine HCl and Pseudoephedrine HCl tablets

Teva Pharmaceutical Industries Ltd. announced today the commercial launch of Fexofenadine Hydrochloride 60 mg and Pseudoephedrine Hydrochloride 120 mg Extended-Release Tablets, the same as the sanofi-aventis U.S. allergy treatment Allegra-D® 12 Hour (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) Extended-Release Tablets. Teva's product is an alternative to the brand product, which had annual sales of approximately $293 million in the United States for the twelve months that ended June 30, 2009, based on IMS sales data.

4 Nov 2009

Financial results for third-quarter 2009 announced by Combinatorx

CombinatoRx, Incorporated today reported financial results for the third quarter ended September 30, 2009.

3 Nov 2009

Raycop's anti-bacterial vacuum cleaning system with UVC technology kills the H1N1 virus

Raycop, the first handheld anti-bacterial vacuum cleaning system and part of the Earlex® brands, offers a proven way to fight the H1N1 virus in the home with its UVC technology. The vac's effects against the virus have been independently tested by a leading international laboratory in August.

3 Nov 2009

Challenges in global health: rising to meet them could save millions of lives, say experts

Responding to the HIV/AIDS pandemic and tackling so-called neglected tropical diseases are the focus of the November/December 2009 edition of Health Affairs. The articles, by leading global health experts from around the world, show that although these challenges differ dramatically, rising to meet them could save millions of lives.

3 Nov 2009

Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint

Schering-Plough Corporation today announced that its investigational sublingual Grass (Phleum Pratense) Allergy Immunotherapy Tablet (AIT) has met the primary endpoint in a Phase III study of adult subjects in the U.S. with a history of grass pollen induced rhinoconjunctivitis with or without asthma. The investigational Grass AIT treatment is designed to work by inducing a protective immune response against grass pollen allergy and providing sustained prevention of allergy symptoms, treating both the symptoms and the underlying cause of the disease.

3 Nov 2009

Pregnant women tolerate the 2009 H1N1 flu vaccine, mount strong immune response

Healthy pregnant women mount a robust immune response following just one dose of 2009 H1N1 influenza vaccine, according to initial results from an ongoing clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

3 Nov 2009

AllOne Health partners with Connectyx Technologies Holdings to provide health information on the Web

AllOne Health(SM) and Connectyx Technologies Holdings Group, Inc. (Pink Sheets: CTYX) today announced a partnership that will allow consumers to view and manage health information on the Web, via portable USB storage devices and through their mobile phones, with one, secure step. A package including both companies' products will be sold in retail stores across the U.S. in December.

2 Nov 2009

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has been awarded a grant for $2.2 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), aimed at advancing the development of novel influenza therapeutics for the treatment of seasonal and pandemic influenza.

2 Nov 2009

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus.

2 Nov 2009

Scientists report a major step forward in the development of an effective therapy against Nipah virus

A collaborative research team from the Uniformed Services University of the Health Sciences (USU), Australian Animal Health Laboratory and National Cancer Institute, a component of the National Institutes of Health, reports a major step forward in the development of an effective therapy against two deadly viruses, Nipah virus and the related Hendra virus.

31 Oct 2009

New tools and interventions can help in eradicating malaria

Although malaria has been controlled in many local and regional populations, the permanent elimination of malaria parasites throughout the world remains an elusive goal, and the disease continues to claim nearly one million lives each year.

31 Oct 2009

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. GBS is the most common cause of sepsis and meningitis in newborns in the United States, according to the Centers for Disease Control and Prevention (CDC). It can also cause severe illness in pregnant women, the elderly and adults with chronic illnesses.

31 Oct 2009

Scientists present new perspective on antigenic drift of flu viruses

Influenza viruses evade infection-fighting antibodies by constantly changing the shape of their major surface protein. This shape-shifting, called antigenic drift, is why influenza vaccines-which are designed to elicit antibodies matched to each year's circulating virus strains-must be reformulated annually.

30 Oct 2009

Research team reports advances in development of an effective therapy against the Nipah and Hendra virus

A collaborative research team from the Uniformed Services University of the Health Sciences (USU), the Australian Animal Health Laboratory (AAHL), and the National Cancer Institute (NCI), National Institutes of Health (NIH) reports a major step forward in the development of an effective therapy against two deadly viruses, Nipah virus and the related Hendra virus.

30 Oct 2009

La Jolla Institute dedicates new Elam Discovery Wall and Type 1 Diabetes Center

The La Jolla Institute for Allergy & Immunology, an international leader in immunology research and San Diego's only research institute focused solely on immune-mediated diseases, today will dedicate its new Elam Discovery Wall and Type 1 Diabetes Center, which will focus on research into novel immunological-focused approaches to type 1 diabetes.

30 Oct 2009

Allergies News and Research

Latest Allergies News and Research

NIAID renews contract to support inner city asthma research

Stress-reduction workshops for women with history of breast cancer

Aerocrine, PSEC enters into a long-term development agreement

MedInformatix demonstrates its PM and EMR Solution at 2009 AAO Conference

Study sheds light on the rise in childhood asthma in developed countries

Teva Pharmaceutical launches Fexofenadine HCl and Pseudoephedrine HCl tablets

Financial results for third-quarter 2009 announced by Combinatorx

Raycop's anti-bacterial vacuum cleaning system with UVC technology kills the H1N1 virus

Challenges in global health: rising to meet them could save millions of lives, say experts

Schering-Plough's Phase III study of Grass Allergy Immunotherapy meets primary endpoint

Pregnant women tolerate the 2009 H1N1 flu vaccine, mount strong immune response

AllOne Health partners with Connectyx Technologies Holdings to provide health information on the Web

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

Scientists report a major step forward in the development of an effective therapy against Nipah virus

New tools and interventions can help in eradicating malaria

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

Scientists present new perspective on antigenic drift of flu viruses

Research team reports advances in development of an effective therapy against the Nipah and Hendra virus

La Jolla Institute dedicates new Elam Discovery Wall and Type 1 Diabetes Center

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Allergies News and Research

Latest Allergies News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in